読み込み中
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
前日終値
$1.94
−$0.01 · -0.51%
時間外
$1.97
+$0.03 · +1.55%
10月9日 18:13 ET
日中の時刻はETです。市場データは遅延する場合があります。
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
日中レンジ
現在 $1.94
52週レンジ
現在 $1.94
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
63
強気
リスク
68
高リスク
モメンタム
23
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
日中レンジ
現在 $1.94
52週レンジ
現在 $1.94
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 1588.7万 USD | 396.92万 USD | 2247.15万 USD | — | — |
| 粗利益 | −1588.7万 USD | −396.92万 USD | −2247.15万 USD | — | — |
| 研究開発 | 1588.7万 USD | 1816.15万 USD | 2247.15万 USD | 2535.53万 USD | 2310.89万 USD |
| 販売・一般管理 | 892.28万 USD | 422.18万 USD | 900.46万 USD | 1070.74万 USD | 1308.52万 USD |
| 営業費用 | 892.28万 USD | 2238.33万 USD | 900.46万 USD | 3606.28万 USD | 3619.41万 USD |
| 支払利息 | 64.89万 USD | 74.57万 USD | 67.54万 USD | 108.1万 USD | 114.93万 USD |
| 減価償却費と償却費 | 388.52万 USD | 396.92万 USD | 395.83万 USD | 382.89万 USD | 223.11万 USD |
| 営業利益 | −2480.97万 USD | −2635.25万 USD | −3147.61万 USD | −3606.28万 USD | −3619.41万 USD |
| 純利益 | −2541.11万 USD | −2692.05万 USD | −3236.59万 USD | −3670.07万 USD | −3636.11万 USD |
会社概要が更新されました 2026年10月10日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 1996年8月28日 | $0.0083Irregular | — | — |
配当落ち 1996年8月28日
$0.0083
Irregular
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
